CTOs on the Move

Registrat

www.registrat.com

 
Registrat, Inc. is a Lexington, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.registrat.com
  • 2343 Alexandria Dr Ste 400
    Lexington, KY USA 40504
  • Phone: 859.223.4334

Executives

Name Title Contact Details

Similar Companies

Radioisotope Life Sciences

RLS (Radioisotope Life Sciences), the third-largest nuclear medicine pharmacy network in the United States, owns and operates 31 radiopharmacies across 18 states, offering an extensive portfolio of molecular imaging products. We endeavor to supply the highest quality radiopharmaceuticals in the industry by dispensing 100 percent of injectable unit dose products in clean rooms built to ISO 1644-1 specifications. In support of our commitment to quality, we provide tailored solutions and exceptional service to our more than 1500 customers.

Ascend Therapeutics

Ascend Therapeutics is a Herndon, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Brains Bioceutical

Brains Bioceutical Corp is a globally recognized leader in GMP-certified production of naturally-sourced Active Pharmaceutical Ingredients (API).

Rondo-Pak

Rondo-Pak is a global print and packaging specialist providing effective solutions and comprehensive services to the pharmaceutical and life sciences industries. The company`s portfolio of sophisticated packaging solutions addresses precise requirements for compliance, child resistance, anti-counterfeiting e-pedigree and more. Rondo-Pak has been a recognized leader in pharmaceutical folding cartons for over 70 years, and is a proud part of the Körber Medipak network of companies.

Argentis Pharmaceuticals

arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU. The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc. Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.